Read about Sanofi Genzyme presenting novel data on multiple sclerosis (MS) treatments Lemtrada and Aubagio at AAN 2024 in Boston. New Data on MS Drugs Lemtrada, Aubagio Presented by Sanofi Genzyme
Lemtrada is a monoclonal antibody made by Sanofi Genzyme to treat relapsing forms of multiple sclerosis (MS). The Food and Drug Administration (FDA)
Genzyme Corporation; Grant support: Biogen, Novartis Treatment optimization in MS: Canadian MS Working Group updated recommendations.
The U.S. Food and Drug Administration (FDA) has approved a Genzyme drug for patients with relapsing forms of multiple sclerosis (MS), the company announced.
The Sanofi-Genzyme MS drug Lemtrada reduces relapse rate but doesn't improve disability in a two-year study.
Sanofi said its U.S. subsidiary Genzyme has received approval from the Food and Drug Administration for its multiple-sclerosis drug Lemtrada. sanofis-genzyme-gets-fda-approval-for-ms-drug
Currently marketed drugs Lemtrada (Genzyme) and Zenapax (Blogen Idec/Abbott) will both expand into MS with a focus on relapsing-remitting MS.
Drug Administration (FDA) for the treatment of relapsing forms of multiple sclerosis (MS). Genzyme, a Sanofi company, announced today that
drug called Alemtuzumab being a potential new treatment for people with MS. On the makers, Genzyme, announced that the company has made an
Comments
Always a living fan,
Santacruzman